Tags

Type your tag names separated by a space and hit enter

Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction.
Am Rev Respir Dis. 1993 Jun; 147(6 Pt 1):1431-5.AR

Abstract

ICI 204,219 is a potent and specific leukotriene D4 receptor antagonist that blocks both the early and late responses to allergen challenge in humans when given orally at a dose of 40 mg. Here we report our findings with an inhaled formulation of ICI 204,219 against allergen-induced bronchoconstriction. A group of 10 atopic subjects (mean age 25.6 +/- 4.2; 6 females; FEV1 > 90% of predicted; on inhaled beta 2-agonists only) were studied on 2 separate days 2 to 3 wk apart. In a randomized placebo-controlled trial they inhaled eight puffs of a standard metered dose inhaler containing either ICI 204,219 (200 micrograms/puff, total dose 1,600 micrograms) or propellant alone. They underwent bronchial allergen challenge 30 min later using a single concentration of allergen previously shown to lower the FEV1 by > or = 15%. FEV1 was monitored hourly for 10 h, and urine was collected for LTE4 determination. Inhalation of ICI 204,219 was well tolerated, with no adverse clinical or biochemical effects. There was no significant effect of ICI 204,219 inhalation on basal airway caliber (change in FEV1 30 min after inhalation was -149 +/- 67 ml after placebo versus 3 +/- 38 ml after ICI 204,219; p = 0.08). The early response to allergen was significantly inhibited by ICI 204,219 (the maximum fall in FEV1 was -21.2 +/- 6.1% after ICI 204,219 compared with -38.8 +/- 6.5% on placebo; p = 0.007).(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Department of Clinical Pharmacology and Medicine, Royal Postgraduate Medical School, London, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8389105

Citation

O'Shaughnessy, K M., et al. "Potent Leukotriene D4 Receptor Antagonist ICI 204,219 Given By the Inhaled Route Inhibits the Early but Not the Late Phase of Allergen-induced Bronchoconstriction." The American Review of Respiratory Disease, vol. 147, no. 6 Pt 1, 1993, pp. 1431-5.
O'Shaughnessy KM, Taylor IK, O'Connor B, et al. Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis. 1993;147(6 Pt 1):1431-5.
O'Shaughnessy, K. M., Taylor, I. K., O'Connor, B., O'Connell, F., Thomson, H., & Dollery, C. T. (1993). Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. The American Review of Respiratory Disease, 147(6 Pt 1), 1431-5.
O'Shaughnessy KM, et al. Potent Leukotriene D4 Receptor Antagonist ICI 204,219 Given By the Inhaled Route Inhibits the Early but Not the Late Phase of Allergen-induced Bronchoconstriction. Am Rev Respir Dis. 1993;147(6 Pt 1):1431-5. PubMed PMID: 8389105.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. AU - O'Shaughnessy,K M, AU - Taylor,I K, AU - O'Connor,B, AU - O'Connell,F, AU - Thomson,H, AU - Dollery,C T, PY - 1993/6/1/pubmed PY - 1993/6/1/medline PY - 1993/6/1/entrez SP - 1431 EP - 5 JF - The American review of respiratory disease JO - Am Rev Respir Dis VL - 147 IS - 6 Pt 1 N2 - ICI 204,219 is a potent and specific leukotriene D4 receptor antagonist that blocks both the early and late responses to allergen challenge in humans when given orally at a dose of 40 mg. Here we report our findings with an inhaled formulation of ICI 204,219 against allergen-induced bronchoconstriction. A group of 10 atopic subjects (mean age 25.6 +/- 4.2; 6 females; FEV1 > 90% of predicted; on inhaled beta 2-agonists only) were studied on 2 separate days 2 to 3 wk apart. In a randomized placebo-controlled trial they inhaled eight puffs of a standard metered dose inhaler containing either ICI 204,219 (200 micrograms/puff, total dose 1,600 micrograms) or propellant alone. They underwent bronchial allergen challenge 30 min later using a single concentration of allergen previously shown to lower the FEV1 by > or = 15%. FEV1 was monitored hourly for 10 h, and urine was collected for LTE4 determination. Inhalation of ICI 204,219 was well tolerated, with no adverse clinical or biochemical effects. There was no significant effect of ICI 204,219 inhalation on basal airway caliber (change in FEV1 30 min after inhalation was -149 +/- 67 ml after placebo versus 3 +/- 38 ml after ICI 204,219; p = 0.08). The early response to allergen was significantly inhibited by ICI 204,219 (the maximum fall in FEV1 was -21.2 +/- 6.1% after ICI 204,219 compared with -38.8 +/- 6.5% on placebo; p = 0.007).(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0003-0805 UR - https://www.unboundmedicine.com/medline/citation/8389105/Potent_leukotriene_D4_receptor_antagonist_ICI_204219_given_by_the_inhaled_route_inhibits_the_early_but_not_the_late_phase_of_allergen_induced_bronchoconstriction_ L2 - https://www.atsjournals.org/doi/10.1164/ajrccm/147.6_Pt_1.1431?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -